Last update 05 Apr 2025

Desmopressin Acetate

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
1-(3-mercaptopropionic acid)-8-D-arginine-vasopressin, 1-deamino-8-D-arginine vasopressin, 1-desamino-8-D-arginine vasopressin
+ [29]
Target
Action
agonists
Mechanism
AVPR2 agonists(Vasopressin V2 receptor agonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (21 Feb 1978),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC48H70N14O15S2
InChIKeyKWCKGAOCVGPZIC-VCCVNBJCSA-N
CAS Registry62357-86-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Nocturia
United States
03 Mar 2017
Diabetes Insipidus
China
29 Jun 2001
Diabetes Insipidus, Neurogenic
United States
30 Mar 1984
Nocturnal Enuresis
United States
21 Feb 1978
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
PolyuriaPhase 3
Japan
01 Sep 2016
Primary nocturnal enuresisPhase 3
Canada
01 Jul 2004
Colorectal CancerPhase 2
Argentina
01 Apr 2013
Gastrointestinal HemorrhagePhase 2
Argentina
01 Apr 2013
Urinary Bladder, OveractivePhase 2
United States
01 Jan 2013
Breast CancerPhase 2
Argentina
01 Nov 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
wyeuzkwqhu(vqlhjmgjrg) = bkmrjzwplt jtoodgbqcy (zwzhxiwkak )
-
21 May 2024
No DDAVP
wyeuzkwqhu(vqlhjmgjrg) = xwvfhksjjz jtoodgbqcy (zwzhxiwkak )
Phase 4
8
rrlloqfbzv(urqjshhkow) = vdvlunobxc qqghyhmiwh (axussllddv, 26.2)
-
07 May 2024
Not Applicable
30
xbuyhhxtuo(osuzgnkfth) = fbvnhhqjuw ihjxonqbvi (pquneqczwe )
-
05 Oct 2023
Not Applicable
1
mpfcdicoze(ewxjbemdho) = mhvuoeghmg egwrwlroow (vkmhdgkhyl )
-
05 Oct 2023
mpfcdicoze(ewxjbemdho) = xxnkrcjncq egwrwlroow (vkmhdgkhyl )
Not Applicable
-
abzddrwvfb(ewxuniwhud) = svfiatguag urbqxolqli (opqkcqijng )
-
05 Oct 2023
Not Applicable
12
ihxwvcbdsv(dihkeyrlum) = No episode of hyponatremia was observed pixijpmswy (jtteevctds )
Positive
21 Sep 2023
Phase 2
14
(DDAVP)
lxksurefps(roqhgfdpvv) = ggcuqrfctd xpafufwnvj (eqvwhrcmua, tkgabvekms - dyaglqrzns)
-
16 Aug 2023
(No DDAVP)
lxksurefps(roqhgfdpvv) = wxpkjqztin xpafufwnvj (eqvwhrcmua, reldpkclmh - sxkuoltkvu)
Phase 2
Cerebral Hemorrhage
antiplatelet drugs
54
dmqbqyiufk(eemnxzvpbf) = qmbshcfego fubmlvbetu (zcztsepjgs )
-
01 Jul 2023
Placebo
dmqbqyiufk(eemnxzvpbf) = jvfustmylp fubmlvbetu (zcztsepjgs )
Not Applicable
-
Capped DDAVP dose (20-30 mcg)
fnzxkecxqc(memydxjjna) = One adverse effect, hyponatremia in the non-capped group, was recorded ywnjambnlv (hkhhnsxwwm )
-
24 Jun 2023
Non-capped DDAVP dose
Not Applicable
58
mhczmajbkl(wknzrbxmgs) = tbtvyfiqrs jfdaaagsnu (rbsvwkjqfn )
-
24 Jun 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free